BioStem Technologies's earnings per share without non-recurring items for the
three
months ended in Sep. 2025 was $0.03.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2025 was $0.71.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for BioStem Technologies's EPS without NRI or its related term are showing as below:
During the past 13 years, BioStem Technologies's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 80.50% per year. The lowest was -68.90% per year. And the median was 31.60% per year.
BSEM's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.7 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BioStem Technologies's EPS (Basic) for the
three
months ended in Sep. 2025 was $0.05.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2025 was $1.00.
BioStem Technologies (OTCPK:BSEM) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
BioStem Technologies EPS without NRI Related Terms
BioStem Technologies EPS without NRI Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSEM vs XLO, TCRX, MNOV: EPS without NRI Comparison
For the Biotechnology subindustry, BioStem Technologies's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies (BSEM) has a EPS without NRI of $0.71 as of Sep. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on BioStem Technologies and its competitors. According to the industry distribution chart, BioStem Technologies ranks #999999 out of 1167 companies in the Biotechnology industry.
Is BioStem Technologies' EPS without NRI too high?
BioStem Technologies' current EPS without NRI is $0.71. The Biotechnology industry median EPS without NRI is 16.70. BioStem Technologies' value of $0.71 is 95.7% below this industry median. Based on the distribution chart, BioStem Technologies ranks #999999 out of 1167 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' EPS without NRI compare to XLO and TCRX?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #999999 out of 1167 companies for EPS without NRI. This places BioStem Technologies in the lower half of its industry. The industry median EPS without NRI is 16.70. BioStem Technologies' value of $0.71 is 95.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.70, based on 1,167 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioStem Technologies's current EPS without NRI of $0.71 is 95.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on BioStem Technologies and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioStem Technologies's current EPS without NRI is $0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $141.78, compared to a current price of $3.24 — trading 97.7% below its estimated fair value. The current EPS without NRI is $0.71 and 95.7% below the Biotechnology industry median of 16.70. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current EPS without NRI is $0.71 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioStem Technologies (BSEM) Overvalued in 2026?
Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued.
The current stock price of $3.24 is trading 97.7% below its estimated GF Value™ of $141.78.
GuruFocus considers BioStem Technologies to be Possible Value Trap.
Key valuation signals for BSEM:
EPS without NRI: $0.71
GF Value™: $141.78 vs. price of $3.24 (97.7% below fair value)
Industry Position: 95.7% below the Biotechnology median (#999999 of 1167)
No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score
Get the complete analysis for BSEM
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
